REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Trial details
- Registry ID
- NCT03185013
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03185013 | Inovio Pharmaceuticals | Phase 3 | Completed | 2020-07-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |